PARIS, September 30 /PRNewswire-FirstCall/ --
- 76% Higher Dose of Insulin detemir Needed to Achieve Similar, Well Tolerated Glycemic Control Versus Lantus(R)
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today results of a head-to-head study providing further evidence on the efficacy of once-daily, 24-hour basal insulin Lantus(R) (insulin glargine [rDNA] injection) compared to twice-daily insulin detemir. The study was presented during the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna.
To view the Multimedia News Release, please click:
In the head-to-head, randomised, non-inferiority controlled clinical trial of 964 patients, patients taking Lantus(R) required an average daily dose of 43.5 units to achieve the primary endpoint of HbA1c below 7% without symptomatic hypoglycaemia compared to patients on insulin detemir, who received 76.5 units - an increase of 76% (p<0.001). Despite lower doses of insulin in the glargine group, Lantus(R) once-daily and insulin detemir twice-daily resulted in similar improvements in glycemic control (HbA1c) and a similar risk of hypoglycaemia (primary endpoint: 27.5% vs 25.6%, p=0.52). Patients in the Lantus(R) arm of the study also achieved significantly lower fasting blood glucose (-63.1 mg/dL Lantus(R) vs -57.7 mg/dL, p<0.001).
"This study demonstrated that for insulin-naive patients with type 2
diabetes, initiating insulin therapy with once-daily glargine achieved the
same glycemic control as twice-daily detemir, with somewhat more weight gain,
but lower insulin doses", stated Study Investigator Hertzel Gerstein,
Professor of Diabetes Medicine
|SOURCE Sanofi Aventis Groupe|
Copyright©2009 PR Newswire.
All rights reserved